top of page
Grey Round Patterns
Sherringford's logo
You can find all our articles at portalnotes.app
We have moved to sherringford.org and portalnotes.app

CagriSema Outperforms Wegovy in Latest Late-Stage Diabetes Trial

Feb 3
2 min read

Updated: Feb 3

This image features a novo nordisk logo accompanied by a blue DNA helix and a green leaf on a clean, bright white background.

Novo Nordisk reported on February 2, 2026, that its next-generation experimental shot, CagriSema, successfully met primary objectives in a Phase 3 clinical trial. The study, known as REIMAGINE 2, involved over 2,700 adults with Type 2 diabetes who were also classified as overweight or obese.


CagriSema is a fixed-dose combination of semaglutide (the active ingredient in Wegovy and Ozempic) and cagrilintide, an analog that mimics the pancreatic hormone amylin. In the 68-week trial, participants receiving the 2.4-mg dose of CagriSema achieved a 1.91 percentage point reduction in HbA1c (a marker of long-term blood sugar), compared to a 1.76 point reduction for those on semaglutide alone.


The drug also demonstrated superior weight-loss capabilities. Participants on CagriSema lost 14.2% of their body weight, while those treated with Wegovy lost 10.2%. Despite these gains, the drug fell short of Novo’s internal benchmark of 25% weight loss, a target analysts described as "lofty".


The data strengthens Novo Nordisk’s position in its rivalry with Eli Lilly, whose drug Zepbound has become a global leader in the obesity market. While CagriSema’s current results appear numerically lower than some of Zepbound’s previous data, a high-stakes head-to-head trial comparing the two is expected to release results by the end of March 2026.


Novo Nordisk filed for FDA approval of CagriSema as a weight-loss treatment in December 2025. Martin Holst Lange, Novo’s chief scientific officer, stated that the drug could become the first amylin-based combination therapy on the market, offering a promising option for individuals managing both diabetes and weight loss. Side effects reported were typical of GLP-1 therapies, primarily involving gastrointestinal issues like nausea.



🔖 Sources






Keywords: CagriSema Outperforms Wegovy

CagriSema Outperforms Wegovy



Sherringford logo

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating

We designed Sherringford.org to be more than just an educational resource; it is a platform created to bring a fresh perspective to your daily professional life.

 

To achieve this ambitious goal, we decided to upgrade our site, and we invite you to visit our new space at

 

sherringford.org

​

We designed Sherringford.org to be more than just an educational resource; it is a platform created to bring a fresh perspective to your daily professional life.

 

To achieve this ambitious goal, we decided to upgrade our site, and we invite you to visit our new space at sherringford.org.

bottom of page